MTORC2 balances AKT activation and eIF2α serine 51 phosphorylation to promote survival under stress

Molecular Cancer Research

Volumn 13, Issue 10, 2015, Pages 1377-1388

  Tenkerian, Clara ^a,b   Krishnamoorthy, Jothilatha ^a   Mounir, Zineb ^c   Kazimierczak, Urszula ^a,d   Khoutorsky, Arkady ^e   Staschke, Kirk A ^f   Kristof, Arnold S ^g,h   Wang, Shuo ^a   Hatzoglou, Maria ⁱ   Koromilas, Antonis E ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c GENENTECH INC   (United States)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^e MCGILL UNIVERSITY   (Canada)

^f ELI LILLY AND COMPANY   (United States)

^g MCGILL UNIVERSITY   (Canada)

^h MCGILL UNIVERSITY   (Canada)

ⁱ CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 [2 (2,6 DIMETHYLMORPHOLINO) 4 MORPHOLINOPYRIDO[2,3 D]PYRIMIDIN 7 YL] 2 METHOXYBENZENEMETHANOL; BORTEZOMIB; GSK 2656157; INITIATION FACTOR; INITIATION FACTOR 2 ALPHA SERINE 51 PHOSPHORYLATION; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE R ENDOPLASMIC RETICULUM KINASE; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAPAMYCIN; TACROLIMUS; THAPSIGARGIN; TORIN 2; TUBERIN; TUMOR MARKER; UNCLASSIFIED DRUG; INITIATION FACTOR 2; MULTIPROTEIN COMPLEX; PERK KINASE; PROTEIN KINASE R; SERINE; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL MUTANT; CELL STRESS; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FIBROSARCOMA; GENETIC TRANSFECTION; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; EIF-2 KINASE; ENDOPLASMIC RETICULUM STRESS; EUKARYOTIC INITIATION FACTOR-2; FIBROSARCOMA; HUMANS; MICE; MULTIPROTEIN COMPLEXES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SERINE; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRANSFECTION; UP-REGULATION;

EID: 84945282440     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-15-0184-T     Document Type: Article

References (54)

1. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274-93.
2. Dazert E, Hall MN. mTOR signaling in disease. Curr Opin Cell Biol 2011;23:744-55.
3. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011;12:21-35.
4. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-74.
5. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307:1098-101.
6. Tomasoni R, Mondino A. The tuberous sclerosis complex: balancing proliferation and survival. Biochem Soc Trans 2011;39:466-71.
7. Mieulet V, Lamb RF. Tuberous sclerosis complex: linking cancer to metabolism. Trends Mol Med 2010;16:329-35.
8. Leung AK, Robson WL. Tuberous sclerosis complex: a review. J Pediatr Health Care 2007;21:108-14.
9. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009;10:307-18.
10. Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 2009;136:731-45.
11. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004;166:213-23.
12. Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 2004;14:1650-6.
13. Huang J, Manning BD. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans 2009;37:217-22.
14. Koromilas AE. Roles of the translation initiation factor eIF2alpha serine 51 phosphorylationincancerformationandtreatment. Biochim Biophys Acta 2015;1849:871-80.
15. Hinnebusch AG. Translational regulation of GCN4 and the general amino acid control of yeast. Annu Rev Microbiol 2005;59:407-50.
16. Rutkowski DT, Kaufman RJ. All roads lead to ATF4. Dev Cell 2003;4:442-4.
17. Wang M, Kaufman RJ. The impact of the enoplasmic reticulum protein-folding environment on cancer development. Nat Rev Cancer 2014; 14:581-97.
18. Ron D, Harding HP. Protein-folding homeostasis in the endoplasmic reticulum and nutritional regulation. Cold Spring Harb Perspect Biol 2012;4:a013177.
19. Costa-Mattioli M, Sossin WS, Klann E, Sonenberg N. Translational control of long-lasting synaptic plasticity and memory. Neuron 2009;61:10-26.
20. Ohno M. Roles of eIF2alpha kinases in the pathogenesis of Alzheimer's disease. Front Mol Neurosci 2014;7:22.
21. Marchal JA, Lopez GJ, Peran M, Comino A, Delgado JR, Garcia-Garcia JA, et al. The impact of PKR activation: from neurodegeneration to cancer. FASEB J 2014;28:1965-74.
22. Koromilas AE, Mounir Z. Control of oncogenesis by eIF2alpha phosphorylation: implications in PTEN and PI3K-Akt signaling and tumor treatment. Future Oncol 2013;9:1005-15.
23. Zinzalla V, Stracka D, Oppliger W, Hall MN. Activation of mTORC2 by association with the ribosome. Cell 2011;144:757-68.
24. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene 2006;25:6416-22.
25. Tuval-Kochen L, Paglin S, Keshet G, Lerenthal Y, Nakar C, Golani T, et al. Eukaryotic initiation factor 2alpha - a downstream effector of mammalian target of rapamycin-modulates DNA repair and cancer response to treatment. PLoS ONE 2013;8:e77260.
26. Ozcan U, Ozcan L, Yilmaz E, Duvel K, Sahin M, Manning BD, et al. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell 2008;29:541-51.
27. Gangloff YG, Mueller M, Dann SG, Svoboda P, Sticker M, Spetz JF, et al. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol Cell Biol 2004;24:9508-16.
28. Cybulski N, Zinzalla V, Hall MN. Inducible raptor and rictor knockout mouse embryonic fibroblasts. Methods Mol Biol 2012;821:267-78.
29. Huang J, Dibble CC, Matsuzaki M, Manning BD. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol 2008;28:4104-15.
30. Yu J, Henske EP. mTOR activation, lymphangiogenesis, and estrogenmediated cell survival: the "perfect storm" of pro-metastatic factors in LAM pathogenesis. Lymphat Res Biol 2010;8:43-9.
31. Krishnamoorthy J, Rajesh K, Mirzajani F, Kesoglidou P, Papadakis AI, Koromilas AE. Evidence for eIF2alpha phosphorylation-independent effects of GSK2656157, a novel catalytic inhibitor of PERK with clinical implications. Cell Cycle 2014;13:801-6.
32. Mounir Z, Krishnamoorthy JL, Wang S, Papadopoulou B, Campbell S, Muller WJ, et al. Akt determines cell fate through inhibition of the PERK-eIF2{alpha} phosphorylation pathway. Sci Signal 2011;4:ra62.
33. Ma Y, Lu Y, Zeng H, Ron D, Mo W, Neubert TA. Characterization of phosphopeptides from protein digests using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and nanoelectrospray quadrupole time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 2001;15:1693-700.
34. Garcia-Martinez JM, Moran J, Clarke RG, Gray A, Cosulich SC, Chresta CM, et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J 2009;421:29-42.
35. Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 2011;10:868-80.
36. Manning BD, Logsdon MN, Lipovsky AI, Abbott D, Kwiatkowski DJ, Cantley LC. Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev 2005;19:1773-8.
37. Axten JM, Medina JR, Feng Y, Shu A, Romeril SP, Grant SW, et al. Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-p yrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). J Med Chem 2012;55: 7193-207.
38. Donze O, Jagus R, Koromilas AE, Hershey JW, Sonenberg N. Abrogation of translation initiation factor eIF-2 phosphorylation causes malignant transformation of NIH 3T3 cells. EMBO J 1995;14:3828-34.
39. Vattem KM, Wek RC. Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells. Proc Natl Acad Sci U S A 2004;101:11269-74.
40. Kang YJ, Lu MK, Guan KL. The TSC1 and TSC2 tumor suppressors are required for proper ER stress response and protect cells from ER stress-induced apoptosis. Cell Death Differ 2011;18:133-44.
41. Rajesh K, Papadakis AI, Kazimierczak U, Peidis P, Wang S, Ferbeyre G, et al. eIF2alpha phosphorylation bypasses premature senescence caused by oxidative stress and pro-oxidant antitumor therapies. Aging 2013; 5:884-901.
42. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Dunner K Jr, Huang P, et al. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 2005;65:11658-66.
43. Nawrocki ST, Carew JS, Dunner K Jr, Boise LH, Chiao PJ, Huang P, et al. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 2005;65:11510-9.
44. Sanidas I, Polytarchou C, Hatziapostolou M, Ezell SA, Kottakis F, Hu L, et al. Phosphoproteomics screen reveals akt isoform-specific signals linking RNA processing to lung cancer. Mol Cell 2014;53: 577-90.
45. Ahearn IM, Tsai FD, Court H, Zhou M, Jennings BC, Ahmed M, et al. FKBP12 binds to acylated H-ras and promotes depalmitoylation. Mol Cell 2011;41:173-85.
46. Osman B, Doller A, Akool el-S, Holdener M, Hintermann E, Pfeilschifter J, et al. Rapamycin induces the TGFbeta1/Smad signaling cascade in renal mesangial cells upstream of mTOR. Cell Signal 2009;21: 1806-17.
47. Galat A. Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity-targets-functions. Curr Top Med Chem 2003;3:1315-47.
48. Yao YL, Liang YC, Huang HH, Yang WM. FKBPs in chromatin modification and cancer. Curr Opin Pharmacol 2011;11:301-7.
49. Kato H, Nakajima S, Saito Y, Takahashi S, Katoh R, Kitamura M. mTORC1 serves ER stress-triggered apoptosis via selective activation of the IRE1-JNK pathway. Cell Death Differ 2012;19:310-20.
50. Tyagi R, Shahani N, Gorgen L, Ferretti M, Pryor W, Chen PY, et al. Rheb inhibits protein synthesis by activating the PERK-eIF2alpha signaling cascade. Cell Rep 2015;S2211-1247:00027-3.
51. Babcock JT, Nguyen HB, He Y, Hendricks JW, Wek RC, Quilliam LA. Mammalian target of rapamycin complex 1 (mTORC1) enhances bortezomib-induced death in tuberous sclerosis complex (TSC)-null cells by a c-MYC-dependent induction of the unfolded protein response. J Biol Chem 2013;288:15687-98.
52. Siroky BJ, Yin H, Babcock JT, Lu L, Hellmann AR, Dixon BP, et al. Human TSC-associated renal angiomyolipoma cells are hypersensitive to ER stress. Am J Physiol Renal Physiol 2012;303:F831-44.
53. Kwiatkowski DJ. Animal models of lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC). Lymphat Res Biol 2010;8:51-7.
54. Wienecke R, Fackler I, Linsenmaier U, Mayer K, Licht T, Kretzler M. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am J Kidney Dis 2006;48:e27-e29.